| A. Univariate analysis of the association of PIK3CA mutations, KRAS mutations, and PTEN protein expression with clinical outcome of mCRC patients treated with the anti-EGFR monoclonal antibodies cetuximab or panitumumab. Responders are patients who achieved PR; nonresponders are PD and SD (RECIST) . | . | . | . | . | . | . | . | . | . | . | . | . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | PIK3CA . | . | . | KRAS . | . | . | PIK3CA and/or KRAS . | . | . | PTEN . | . | . | ||||||||||||
| . | WT (%) . | Mut (%) . | P . | WT (%) . | Mut (%) . | P . | WT (%) . | Mut (%) . | P . | Normal (%) . | Loss (%) . | P . | ||||||||||||
| Objective response | ||||||||||||||||||||||||
| Responders | 22 (100) | 0 (0) | 0.038 | 20 (90.9) | 2 (9.1) | 0.019 | 20 (90.9) | 2 (9.1) | 0.001 | 17 (94.4) | 1 (5.6) | 0.001 | ||||||||||||
| Nonresponders | 73 (82.9) | 15 (17.1) | 57 (65.5) | 30 (34.5) | 44 (50.6) | 43 (49.4) | 32 (50.8) | 31 (42.2) | ||||||||||||||||
| B. Multivariate logistic regression of the association between PIK3CA mutations, KRAS mutations, and PTEN protein expression and objective response (any single P value is adjusted with respect to other regressors); | ||||||||||||||||||||||||
| OR (95% CI for OR) | P | |||||||||||||||||||||||
| PIK3CA (mutated vs WT) | 0.1153 (0.000–0.865) | 0.0337 | ||||||||||||||||||||||
| KRAS (mutated vs WT) | 0.0660 (0.000–0.452) | 0.0029 | ||||||||||||||||||||||
| PTEN (loss vs normal) | 0.0547 (0.001–0.430) | 0.0012 | ||||||||||||||||||||||
| C. Multivariate Cox survival analysis of the association between KRAS mutations, PIK3CA mutations, and/or PTEN loss and risk of progression | ||||||||||||||||||||||||
| HR (CI95% for HR) | P | |||||||||||||||||||||||
| KRAS (mutated vs WT) | 1.4974 (0.8909–2.5170) | 0.128 | ||||||||||||||||||||||
| PIK3CA/PTEN (at least one alterated vs normal) | 1.8576 (1.1637–2.9653) | 0.009 | ||||||||||||||||||||||
| A. Univariate analysis of the association of PIK3CA mutations, KRAS mutations, and PTEN protein expression with clinical outcome of mCRC patients treated with the anti-EGFR monoclonal antibodies cetuximab or panitumumab. Responders are patients who achieved PR; nonresponders are PD and SD (RECIST) . | . | . | . | . | . | . | . | . | . | . | . | . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | PIK3CA . | . | . | KRAS . | . | . | PIK3CA and/or KRAS . | . | . | PTEN . | . | . | ||||||||||||
| . | WT (%) . | Mut (%) . | P . | WT (%) . | Mut (%) . | P . | WT (%) . | Mut (%) . | P . | Normal (%) . | Loss (%) . | P . | ||||||||||||
| Objective response | ||||||||||||||||||||||||
| Responders | 22 (100) | 0 (0) | 0.038 | 20 (90.9) | 2 (9.1) | 0.019 | 20 (90.9) | 2 (9.1) | 0.001 | 17 (94.4) | 1 (5.6) | 0.001 | ||||||||||||
| Nonresponders | 73 (82.9) | 15 (17.1) | 57 (65.5) | 30 (34.5) | 44 (50.6) | 43 (49.4) | 32 (50.8) | 31 (42.2) | ||||||||||||||||
| B. Multivariate logistic regression of the association between PIK3CA mutations, KRAS mutations, and PTEN protein expression and objective response (any single P value is adjusted with respect to other regressors); | ||||||||||||||||||||||||
| OR (95% CI for OR) | P | |||||||||||||||||||||||
| PIK3CA (mutated vs WT) | 0.1153 (0.000–0.865) | 0.0337 | ||||||||||||||||||||||
| KRAS (mutated vs WT) | 0.0660 (0.000–0.452) | 0.0029 | ||||||||||||||||||||||
| PTEN (loss vs normal) | 0.0547 (0.001–0.430) | 0.0012 | ||||||||||||||||||||||
| C. Multivariate Cox survival analysis of the association between KRAS mutations, PIK3CA mutations, and/or PTEN loss and risk of progression | ||||||||||||||||||||||||
| HR (CI95% for HR) | P | |||||||||||||||||||||||
| KRAS (mutated vs WT) | 1.4974 (0.8909–2.5170) | 0.128 | ||||||||||||||||||||||
| PIK3CA/PTEN (at least one alterated vs normal) | 1.8576 (1.1637–2.9653) | 0.009 | ||||||||||||||||||||||
NOTE: P values measured by Fisher's exact test.
Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; HR, hazard ratio.